Stay updated on Safety and Efficacy of Anti-PD-1 Combination Therapies Clinical Trial
Sign up to get notified when there's something new on the Safety and Efficacy of Anti-PD-1 Combination Therapies Clinical Trial page.

Latest updates to the Safety and Efficacy of Anti-PD-1 Combination Therapies Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedAdded revision v3.5.0 to the history and removed revision v3.4.3 from the list.SummaryDifference0.0%

- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedA new revision entry v3.4.3 was added to the history, and the previous v3.4.2 entry was removed.SummaryDifference0.0%

- Check55 days agoChange DetectedAdded a Revision: v3.4.2 to the history; removed the prior funding-status notices about lapses and operating updates.SummaryDifference0.3%

- Check62 days agoChange DetectedAdded a site-wide funding/operational status notice and updated the page revision to v3.4.1 (replacing v3.4.0). These changes do not alter the trial record content.SummaryDifference0.3%

- Check69 days agoChange DetectedThe BI 754091 platform trial description was deleted and replaced with an Ezabenlimab-based platform trial description, and a new 'Results Posted' entry was added, with color-coded changes for Adverse Events, Outcome Measures, IPDSharing, and Study Status. The update also enables 'Show glossary' and documents the 3.4.0 revision with UI cues about how additions and deletions are presented.SummaryDifference0.8%

- Check83 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4 on the page, representing a minor site update with no impact on study records or history content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to Safety and Efficacy of Anti-PD-1 Combination Therapies Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety and Efficacy of Anti-PD-1 Combination Therapies Clinical Trial page.